Reviewing MediciNova Inc. (MNOV)’s and VIVUS Inc. (NASDAQ:VVUS)’s results

Both MediciNova Inc. (NASDAQ:MNOV) and VIVUS Inc. (NASDAQ:VVUS) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediciNova Inc. 10 0.00 N/A -0.35 0.00
VIVUS Inc. 4 0.61 N/A -3.22 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 provides MediciNova Inc. and VIVUS Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MediciNova Inc. 0.00% -21.1% -20.1%
VIVUS Inc. 0.00% 90.4% -11.4%

Volatility & Risk

A beta of 1.18 shows that MediciNova Inc. is 18.00% more volatile than S&P 500. Competitively, VIVUS Inc.’s beta is 1.79 which is 79.00% more volatile than S&P 500.


MediciNova Inc. has a Current Ratio of 34.8 and a Quick Ratio of 34.8. Competitively, VIVUS Inc.’s Current Ratio is 4 and has 3.5 Quick Ratio. MediciNova Inc.’s better ability to pay short and long-term obligations than VIVUS Inc.

Analyst Ratings

In next table is given MediciNova Inc. and VIVUS Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MediciNova Inc. 0 0 1 3.00
VIVUS Inc. 0 0 0 0.00

MediciNova Inc. has a 149.43% upside potential and a consensus price target of $22.

Institutional and Insider Ownership

Institutional investors owned 21.3% of MediciNova Inc. shares and 17.1% of VIVUS Inc. shares. Insiders owned 2.7% of MediciNova Inc. shares. Comparatively, insiders own roughly 2.1% of VIVUS Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MediciNova Inc. -3.54% -2.05% -13.74% 11.58% 0.21% 16.77%
VIVUS Inc. 1.21% -12.79% -9.73% -29.24% -51.56% 49.78%

For the past year MediciNova Inc. has weaker performance than VIVUS Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company’s product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.